Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
Molecular model in a laboratory setting

Jul 22, 2026

R&D Is Investing in AI, Just Not Where It Matters Most

The pharmaceutical industry is poised to invest $25 billion in AI by 2030, driven by the promise of enhanced drug discovery and decision-making. However, a concerning trend is emerging: adoption rates for AI in critical areas of drug discovery, such as generative design and biomarker analysis, are significantly lagging. A primary reason for this disconnect is the fragmented data environment that underpins AI applications, rather than the technology itself.Despite substantial financial commitment
A server rack in a data center with glowing lights and cables

Jul 21, 2026

Pharma Giant and NVIDIA Join Forces to Build the Most Powerful AI Supercomputer Yet

Bristol Myers Squibb (BMS) and NVIDIA are collaborating to create a groundbreaking AI supercomputer aimed at revolutionizing drug development in the pharmaceutical industry.The partnership is set to launch the supercomputer in January 2027, with infrastructure support from Equinix. This initiative reflects a broader trend within the industry as companies increasingly adopt artificial intelligence to enhance drug discovery processes and reduce operational costs. BMS researchers will utilize NVIDI
Petri dish with cell cultures and research notes in a lab

Jul 21, 2026

Sightera Bio secures €3 million for AI drug discovery platform

Sightera Biosciences has successfully secured €3 million in pre-seed funding to enhance its AI-driven drug discovery platform, focusing on oncology and fibrosis.The Antwerp-based startup plans to utilize this funding to expand its team, advance its technology, and move its lead oncology program toward preclinical candidate selection. Additionally, Sightera aims to strengthen partnerships with pharmaceutical and biotech firms. The funding round was led by Entourage, Anacura, and QBIC, highlightin
Silhouette of a supercomputer with GPUs

Jul 21, 2026

BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's.

Bristol Myers Squibb (BMS) has announced the acquisition of an NVIDIA DGX SuperPOD, which it claims is the most powerful and energy-efficient AI supercomputer in life sciences. This announcement comes after Eli Lilly and Roche made their own claims about leading AI supercomputing capabilities within the industry.BMS's new system is an expansion of its existing infrastructure, which has been in operation since 2024. The new setup will integrate eight racks of Vera Rubin NVL72 systems, featuring 5
A minimalist illustration of a pill and molecular structure representing AI drug discovery.

Jul 20, 2026

AI Drug Discovery

Insilico Medicine has made significant strides in AI drug discovery, as evidenced by its latest advancement into Phase III trials for Rentosertib, a treatment for idiopathic pulmonary fibrosis (IPF).This development showcases the capabilities of Insilico's Pharma.AI platform, which effectively identifies disease targets and designs new drug candidates. The AI-driven approach not only streamlines the drug development process—from target identification to clinical trial optimization—but also highl
A glass vial and research notebook in a dimly lit lab

Jul 20, 2026

Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec

Bristol Myers Squibb is significantly enhancing its AI capabilities through a partnership with Nvidia, aiming to establish a highly advanced AI infrastructure in the life sciences sector.In a strategic move, Bristol Myers Squibb (BMS) is expanding its AI computing framework by integrating Nvidia's DGX SuperPOD, which features the Vera Rubin NVL72 systems. This new infrastructure is touted to deliver up to ten times the performance efficiency per megawatt compared to previous systems, thereby enh
DGX SuperPOD in a laboratory

Jul 20, 2026

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Bristol Myers Squibb (BMS) is enhancing its computational capabilities by expanding its collaboration with Nvidia through the deployment of a DGX SuperPOD featuring DGX Vera Rubin NVL72 systems. This upgrade positions BMS to possess the most advanced Nvidia infrastructure dedicated to life sciences, building on nearly three years of partnership with Nvidia.The new Vera Rubin architecture significantly boosts performance, delivering up to ten times greater efficiency per megawatt compared to prev
A minimalist illustration of a molecule and DNA strand for drug discovery.

Jul 20, 2026

BMS Deploys NVIDIA AI Infrastructure for Drug Discovery

Bristol Myers Squibb (BMS) is significantly enhancing its AI capabilities through a collaboration with NVIDIA, focusing on the deployment of advanced DGX SuperPOD systems. This initiative aims to bolster AI-driven drug discovery efforts across BMS’s research portfolio, marking a milestone as it establishes one of the most powerful and energy-efficient AI infrastructures within the life sciences sector.The integration of NVIDIA’s BioNeMo platform will allow BMS to leverage AI models for molecular
A minimalist illustration of a computer chip with energy waves, symbolizing advanced AI infrastructure.

Jul 20, 2026

Bristol Myers Squibb to build the most powerful AI factory in life sciences with NVIDIA

Bristol Myers Squibb (BMS) is set to enhance its computational capabilities by deploying an NVIDIA DGX SuperPOD, establishing one of the most advanced AI infrastructures in the life sciences sector.This new infrastructure will significantly boost BMS's computational power and efficiency, allowing for up to ten times better performance per megawatt compared to previous systems. This advancement enables the company to tackle more complex AI tasks without a proportional increase in energy use, alig
A vial of liquid medication on a laboratory countertop in a dimly lit setting.

Jul 20, 2026

Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer

Bristol Myers Squibb (BMS) has joined the trend of pharmaceutical companies announcing the construction of large AI supercomputers, marking a significant step in leveraging advanced computational power for drug development.In a recent announcement, BMS revealed its plans to build what it claims will be the largest AI supercomputer in the life sciences sector. This follows similar declarations from other pharma companies within the past nine months. Initially, BMS partnered with NVIDIA three year
A flat design of a drug molecule silhouette

Jul 19, 2026

AI-Driven Discovery Platforms

Takeda has entered a strategic partnership with Insilico Medicine to leverage the Pharma AI suite for early-stage drug discovery across various therapeutic areas.This collaboration grants Takeda exclusive global rights to develop, manufacture, and commercialize drug candidates identified through Insilico's AI-driven discovery process. Insilico will spearhead the discovery phase, while Takeda will take selected therapies into clinical development.The Pharma.AI suite encompasses tools such as Pand
A flat illustration of a molecule representing retrosynthesis in a minimalist style.

Jul 17, 2026

Retrosynthesis software bridges pharma agrochemicals and fragrance sectors with advanced route design

Recent advancements in retrosynthesis software are revolutionizing the way chemists across pharmaceuticals, agrochemicals, and fragrance industries approach synthetic route design. Platforms like SYNTHIA utilize expert-coded reaction rules along with extensive chemical libraries to facilitate the synthesis of complex molecules. This technology significantly enhances the efficiency of the design process, allowing for more innovative solutions in drug development, agricultural chemicals, and fragr